Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Amicus Therapeutics Inc is a biotechnology business based in the US. Amicus Therapeutics shares (FOLD) are listed on the NASDAQ and all prices are listed in US Dollars. Amicus Therapeutics employs 483 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Guided investing
Our top pick for
Building a portfolio
Our top pick for
Beginners
| Latest market close | $9.54 |
|---|---|
| 52-week range | $8.40 - $22.15 |
| 50-day moving average | $11.21 |
| 200-day moving average | $10.41 |
| Wall St. target price | $17.33 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-0.90 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $9.54 from 2022-01-19
| 1 week (2022-01-13) | -3.73% |
|---|---|
| 1 month (2021-12-16) | N/A |
| 3 months (2021-10-16) | N/A |
| 6 months (2021-07-20) | 0.21% |
| 1 year (2021-01-20) | -54.64% |
|---|---|
| 2 years (2020-01-17) | -8.36% |
| 3 years (2019-01-18) | 12.31 |
| 5 years (2017-01-20) | 79.32% |
| Revenue TTM | $293.9 million |
|---|---|
| Gross profit TTM | $229.8 million |
| Return on assets TTM | -13.05% |
| Return on equity TTM | -68.47% |
| Profit margin | -81.17% |
| Book value | $1.35 |
| Market capitalisation | $2.9 billion |
TTM: trailing 12 months
We're not expecting Amicus Therapeutics to pay a dividend over the next 12 months.
Over the last 12 months, Amicus Therapeutics's shares have ranged in value from as little as $8.4 up to $22.15. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Amicus Therapeutics's is 1.2098. This would suggest that Amicus Therapeutics's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Amicus Therapeutics, Inc. , a biotechnology company, focuses on discovering, developing, and delivering medicines for people living with rare metabolic diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant based on in vitro assay data; gene therapies for Fabry and Pompe diseases, as well as for various types of Batten diseases; enzyme replacement therapies for Pompe diseases; and CDKL5 deficiency disorder product candidates. The company also has additional gene therapies in active preclinical development, including gene therapies for mucopolysaccharidosis type IIIB, as well as a next generation program in mucopolysaccharidosis type IIIA. The company has collaboration and license agreements with Nationwide Children's Hospital; University of Pennsylvania; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Philadelphia, Pennsylvania.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
Everything we know about the Affinia Therapeutics IPO, plus information on how to buy in.
Everything we know about the Austin Gold IPO, plus information on how to buy in.
Everything we know about the VinFast IPO, plus information on how to buy in.
Everything we know about the Nexalin Technology IPO, plus information on how to buy in.
Everything we know about the Specialty Building Products IPO, plus information on how to buy in.
Everything we know about the HeartCore Enterprises IPO, plus information on how to buy in.
Everything we know about the Credo Technology Group Holding IPO, plus information on how to buy in.
Everything we know about the Hongli Group IPO, plus information on how to buy in.